New research findings are casting a shadow over the once-promising reproductive technique known as mitochondrial replacement therapy (MRT), or "three-parent IVF." Initially hailed for its potential to prevent the inheritance of severe mitochondrial diseases, recent data from the UK and other countries indicate that the procedure's ability to completely eliminate mutated mitochondria may be less robust than anticipated. This has ignited a debate among scientists and ethicists regarding the appropriate and safe development of this innovative technology, particularly concerning its application beyond disease prevention, including for infertility treatment.
While the UK previously reported successful births using MRT to avert mitochondrial mutations, newer observations suggest a concerning phenomenon termed "reversion." This refers to the re-emergence of the mother's original, mutation-carrying mitochondria in the offspring, sometimes at significant levels. This raises critical questions about MRT's long-term effectiveness in preventing disease and its safety, particularly when even a small percentage of mutated mitochondria could potentially lead to health complications.
One key method of MRT, pronuclear transfer, involves swapping nuclear DNA between a biological mother's embryo and a donor egg. Early lab experiments suggested high success in minimizing mutated mitochondria. However, recent follow-up on children born through this method in the UK has revealed low levels of reversion. Similarly, studies in Ukraine, where pronuclear transfer was used for infertility, found higher levels of maternal mitochondria in some children, further underscoring the challenge.
Another MRT technique, maternal spindle transfer, which involves transferring a mother's genetic material into a donor egg before fertilization, has also shown evidence of reversion. Shoukhrat Mitalipov's team at Oregon Health & Science University initially reported healthy outcomes in monkeys, but subsequent human egg studies revealed that even a small carryover of problematic mitochondria could proliferate as cells divide. This led to their coining of the term "reversion," demonstrating that this issue was not merely theoretical but a practical concern in clinical applications.
These findings have led some experts, like embryologist Jacques Cohen, to call for a pause in MRT's use for preventing mitochondrial diseases, advocating for further research into minimizing reversion risks. Others, such as bioethicist Guido Pennings, propose that MRT development should be confined to carefully controlled trials for infertile couples. This approach, they argue, would allow researchers to unravel the complexities of reversion and improve the technique without exposing unborn children to known or unknown risks. Moreover, the potential for complications arising from the mismatch between donor mitochondrial DNA and maternal nuclear DNA, as suggested by some animal studies, adds another layer of concern.
Despite the challenges, there is a growing consensus that clinical trials for MRT in the context of infertility should be re-evaluated. Experts like Esther Braun advocate for changing regulations in countries like the UK and Australia to permit such trials. This would enable a structured approach to determine MRT's efficacy and safety for specific infertility conditions, distinguishing it from the current practice where it is sometimes marketed as a universal solution without sufficient evidence. The urgency for such controlled studies is heightened by the increasing adoption of MRT by commercial clinics as an all-purpose add-on, often lacking clear scientific backing. Researchers are actively proposing staged approaches to responsibly proceed with clinical trials, aiming to define specific infertility subgroups that might genuinely benefit from MRT, thereby ensuring its ethical and safe deployment.
The debate surrounding mitochondrial replacement therapy underscores the critical need for rigorous scientific investigation and transparent ethical considerations in the advancement of reproductive technologies. While the initial promise of preventing severe genetic diseases remains compelling, the emerging evidence of "reversion" necessitates a cautious and methodical approach. Scientists and ethicists are grappling with how to balance the potential benefits of MRT with the imperative to ensure the safety and well-being of future generations. This ongoing discussion highlights the dynamic nature of biomedical innovation and the continuous re-evaluation required to navigate its complex ethical landscape.